EUCTR2005-000535-18-DE进行中（未招募）不适用
Prospective, multicenter study to evaluate the renal safety of 6 mg ibandronic acid infusions over 15 min or 60 min in patients with metastatic bone disease due to breast cancer.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients must meet all of the following criteria in order to be eligible for this study.
- •1. Written informed consent and willingness to participate to and comply with the study.
- •2. Female gender.
- •3. Age: = 18 years.
- •4. Histologically or cytologically confirmed breast cancer.
- •5. At least one osteolytic, mixed or blastic bone metastasis confirmed by X-ray, CT scan or MRI. The assessment is not necessary if it was done within 6 months prior to screening.
- •6. Metastases in other sites should be confirmed by X-ray, abdominal ultrasound or CT scan, if applicable. The assessment is not necessary if it was done within 6 months prior to screening.
- •7. WHO performance status of 0, 1 or 2 at screening.
- •8. If any bisphosphonate therapy is ongoing, the last dose has to be given = 3 weeks prior to start of study medication.
- •9. Antitumour therapies like chemotherapy, endocrine therapy or a therapy with Herceptin® are allowed, but should not be started at the same day as study medication. Patients not receiving any antineoplastic therapy are eligible providing they meet all other inclusion / exclusion criteria.
- •10. Adequate renal function at screening defined by serum creatinine value within normal limits (44.2-120 µmol/l; assessed by central laboratory) and by calculated creatinine clearance = 50 ml/min (Cockcroft-Gault; assessed by central laboratory).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients meeting any one of the following criteria are not eligible for this study.
- •1. Life expectancy = 6 months.
- •2. Known hypersensitivity to ibandronate or other bisphosphonates.
- •3. Patients with unstable pathological renal function defined as serum creatinine value (> 120 µmol/l; assessed by central laboratory) or calculated creatinine clearance < 50 ml/min (Cockcroft-Gault; assessed by central laboratory) within the last 3 months.
- •4. High-dose chemotherapy (i.e. dose intensity > 3 times of standard therapy) within 6 months prior to start of study medication.
- •5. Nephrotoxic chemotherapies like Cisplatin and Methotrexat at study start.
- •6. Radiotherapy during the last 5 weeks.
- •7. Abdominal metastases with renal involvement.
- •8. Active infection of urinary tract at screening. Patient may have a screening once more after recovery.
- •9. Proteinuria > 0.5 g/l (assessed by local laboratory).
- •10. Uncontrolled hypercalcemia at study entry (serum calcium = 3.0 mmol/l (12.0 mg/dl) albumin-corrected).
- •11. Uncontrolled hypocalcemia at study entry (serum calcium = 1.8 mmol/l (7.2 mg/dl) albumin-corrected).
- •12. Actual treatment or treatment within the last 12 weeks prior to start of study medication with aminoglycoside antibiotics, antifungual antibiotics (i.e. Fungizone®) or any other known nephrotoxic medications. Diuretic agents must be stable within the last 4 weeks prior screening (patients with well controlled non-steroidal antirheumatic medication are eligible).
- •13. History of a psychological illness or medical condition such as to interfere with the patient's ability to understand the requirements of the study (i.e. brain metastases after treatment with any impact on cognitive function) as judged by the investigator.
- •14. Patient with organic (i.e. urinary incontinence) or mental disability to follow the instructions to collect 24 h urine sample as judged by the investigator.
- •15. Women lactating, pregnant, of childbearing potential or less than one year after menopause (unless surgically sterile) not using a reliable contraceptive method: intrauterine device, mechanical contraception (condom, diaphragm), oral, injectable or implanted contraceptives or total abstinence. Women of childbearing potential must have a negative pregnancy test (serum) at screening.
- •16. Patients who have received an investigational drug within the last 30 days.
研究者
相似试验
已完成
不适用
A Prospective, Multi-centre Study to Evaluate the Clinical Performance of the GYNECARE PROLIFT +M* Pelvic Floor Repair System as a Device for Pelvic Organ ProlapseProlapse1004682810029903NL-OMON31625Ethicon_Johnson & Johnson Medical Ltd20
尚未招募
不适用
A Prospective, Multi-centre Study to Evaluate the Clinical Performance of TVTO-PA as Treatment for Stress Urinary IncontinenceStress Urinary IncontinenceNL-OMON36399Johnson & Johnson100
尚未招募
不适用
Multi-center cooperative clinical study on the renoprotective effect of DPP-4 inhibitor (Vildagliptin) in Diabetic nephropathy patientsDiabetic nephropathyJPRN-UMIN000010261Faculty of Medicine, Kagawa University40
尚未招募
Unknown
A multicenter retrospective study to evaluate the efficacy and safety of platinum-based chemotherapy in combination with immunotherapy for extensive-stage small cell lung cancer in the real-world settingextensive-stage small cell lung cancerJPRN-UMIN000053134Shinshu University350
招募中
Unknown
To assess the effectiveness of different antibiotics in lung and blood infections caused by carbapenem resistant bacteriaCTRI/2024/02/062846Dr Deepak Govil